
Aster DM Quality Q4 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- QCIL expects continued strong growth momentum in both revenue and margins for the next two years, supported by about 900 additional beds being added in this period.
- Mature hospitals show steady growth (~13.5-14% revenue growth YoY) with EBITDA expansion driven by complexity enhancement and oncology volume growth.
- Emerging and focused units report robust ramp-ups: emerging units grew 62.4% YoY in revenue; focused units grew 21% YoY with improved EBITDA margins.
- Patient volumes are rising with IP volumes up 7-10% yearly and OP footfalls growing similarly, driving revenue increases.
- Expansion plans include adding beds in Raipur, Bhubaneswar, Banjara, Nagercoil (+100 beds), Nampally (+28 beds), Malakpet, Chattogram, Vizag, and Indore (greenfield).
- Continued focus on clinical talent attraction and specialty capability upgrades to enhance case mix and ARPOB (average revenue per occupied bed).
- Growth driven by increasing oncology, cardiology, robotic procedures, and international patient inflows.
- Payor mix favorably shifting towards cash + insurance segments, supporting higher revenue per patient.
See what Aster DM Quality management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Aster DM Quality management said on order book — free account, 30 seconds.
Capex plans
Yes- For FY26, capital expenditure was INR 549 crores, with 45% towards expansion projects.
- Operationalized:
- - Whitefield Block D with 159 beds (April 2026).
- - Aster Ramesh Sanghamitra Ongole brownfield expansion with 75 beds (April 2026).
- Plans to add ~2,500 beds over the next 4 years at a cost of INR 2,700 crores; INR 350 crores invested till March 2026.
- QCIL expansion budget is around INR 2,000 crores for 1,700 beds (1,500 brownfield, 200 greenfield).
- Per bed capex:
- - Brownfield: INR 0.8-1.1 crores.
- - Greenfield: INR 1.5-1.6 crores.
- Focus on sprucing up existing assets, adding clinical capabilities, and enhancing oncology services (e.g., Banjara).
- Addition of 900 beds planned over next two years.
- Expansion and capability enhancement in clusters like Raipur, Bhubaneswar, Banjara, Hyderabad, Nagercoil, and Indore.
Track Aster DM Quality — get its next earnings analysis in your feed
How does Aster DM Quality rank vs peers in Healthcare Services?
Pro featureHow does Aster DM Quality rank in Healthcare Services?
Compare Aster DM Quality against every Healthcare Services company (Q4 FY26) on revenue, margins and earnings-call signals.
Continue your research
What Aster DM Quality's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.